Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.
- Author:
Dong Hoon KIM
1
;
Jongheon SHIN
;
Ho Jeong KWON
Author Information
1. Department of Biotechnology, College of Engineering, Yonsei University, Seoul 120-749, Korea. kwonhj@yonsei.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
antineoplastic agents;
histone deacetylases;
prodrugs;
psammaplin A
- MeSH:
Tyrosine/*analogs & derivatives/chemistry/pharmacology;
Prodrugs/chemistry/*pharmacology;
Oxidation-Reduction;
Molecular Structure;
Humans;
Histones/metabolism;
Histone Deacetylases/*antagonists & inhibitors/*classification/genetics/metabolism;
Hela Cells;
Enzyme Inhibitors/chemistry/*pharmacology;
Disulfides/chemistry/*pharmacology;
Cell Proliferation;
Biological Products/chemistry/*pharmacology;
Acetylation
- From:Experimental & Molecular Medicine
2007;39(1):47-55
- CountryRepublic of Korea
- Language:English
-
Abstract:
Histone deacetylase (HDAC) has been highlighted as one of key players in tumorigenesis and angiogenesis. Recently, several derivatives of psammaplin (Psams) from a marine sponge have been known to inhibit the HDAC activity, but the molecular mechanism for the inhibition has not fully understood. Here, we explored the mode of action of Psams for the inhibition of HDAC activity in the molecular and cellular level. Among the derivatives, psammaplin A (Psam A) showed the potent inhibitory activity in enzyme assay and anti-proliferation assay with IC50 value of 0.003 and 1 microM, respectively. Psam A selectively induced hyperacetylation of histones in the cells, resulting in the upregulation of gelsolin, a well-known HDAC target gene, in a transcriptional level. In addition, reduced Psam A showed a stronger inhibitory activity than that of non-reduced one. Notably, glutathione-depleted cells were not sensitive to Psam A, implying that cellular reduction of the compound is responsible for the HDAC inhibition of Psam A after uptake into the cells. Together, these data demonstrate that Psam A could exhibit its activity under the reduced condition in the cells and be a new natural prodrug targeting HDAC.
